- Home
- GIPR vs KZIA Comparison
GIPR vs KZIA Comparison
Compare GIPR & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GIPR
- KZIA
- Stock Information
- Founded
- GIPR 2015
- KZIA 1994
- Country
- GIPR United States
- KZIA Australia
- Employees
- GIPR N/A
- KZIA N/A
- Industry
- GIPR Real Estate Investment Trusts
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- GIPR Real Estate
- KZIA Health Care
- Exchange
- GIPR Nasdaq
- KZIA Nasdaq
- Market Cap
- GIPR 7.7M
- KZIA 5.1M
- IPO Year
- GIPR 2021
- KZIA 1999
- Fundamental
- Price
- GIPR $1.45
- KZIA $11.43
- Analyst Decision
- GIPR
- KZIA Strong Buy
- Analyst Count
- GIPR 0
- KZIA 2
- Target Price
- GIPR N/A
- KZIA $14.00
- AVG Volume (30 Days)
- GIPR 17.5K
- KZIA 705.9K
- Earning Date
- GIPR 08-14-2025
- KZIA 07-22-2025
- Dividend Yield
- GIPR N/A
- KZIA N/A
- EPS Growth
- GIPR N/A
- KZIA N/A
- EPS
- GIPR N/A
- KZIA N/A
- Revenue
- GIPR $9,711,058.00
- KZIA $1,549,158.00
- Revenue This Year
- GIPR N/A
- KZIA N/A
- Revenue Next Year
- GIPR N/A
- KZIA N/A
- P/E Ratio
- GIPR N/A
- KZIA N/A
- Revenue Growth
- GIPR 11.25
- KZIA 248983.08
- 52 Week Low
- GIPR $1.33
- KZIA $2.86
- 52 Week High
- GIPR $3.92
- KZIA $40.75
- Technical
- Relative Strength Index (RSI)
- GIPR 46.03
- KZIA 76.27
- Support Level
- GIPR $1.46
- KZIA $5.86
- Resistance Level
- GIPR $1.59
- KZIA $11.34
- Average True Range (ATR)
- GIPR 0.07
- KZIA 1.11
- MACD
- GIPR 0.01
- KZIA 0.38
- Stochastic Oscillator
- GIPR 36.36
- KZIA 90.76
About GIPR Generation Income Properties Inc.
Generation Income Properties Inc is an internally managed real estate investment company focused on acquiring and managing income-producing retail, office and industrial properties net leased to high-quality tenants in markets throughout the United States. Its key source of revenue is the rental income. The company holds properties in Alabama, Arizona, Colorado, the District of Columbia, Florida, Illinois, North Carolina and Virginia.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.